Hyperthyroid Disorders

Williams Textbook of Endocrinology

Volumn , Issue , 2015, Pages 369-415

  Davies, Terry F ^a,b   Laurberg, Peter ^c   Bahn, Rebecca S ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85135586555     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-29738-7.00012-5     Document Type: Chapter

References (379)

1. GJ Kahaly and WH Dillmann (2005) Thyroid hormone action in the heart. Endocr Rev 26 704-728
2. J Burggraaf, JH Tulen, S Lalezari, et al. (2001) Sympathovagal imbalance in hyperthyroidism. Am J Physiol Endocrinol Metab 281 E190-E195
3. S Fazio, EA Palmieri, G Lombardi and B Biondi (2004) Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res 59 31-50
4. MA Carrillo-Sepulveda, GS Ceravolo, CR Furstenau, et al. (2013) Emerging role of angiotensin type 2 receptor (AT2R)/Akt/NO pathway in vascular smooth muscle cell in the hyperthyroidism. PLoS One 8 e61982
5. IM Grais and JR Sowers (2014) Thyroid and the heart. Am J Med 127 691-698
6. A Brauman, T Rosenberg, Y Gilboa, et al. (1988) Prevalence of mitral valve prolapse in chronic lymphocytic thyroiditis and nongoitrous hypothyroidism. Cardiology 75 269-273
7. ME Evangelopoulos, S Toumanidis, D Sotou, et al. (2009) Mitral valve prolapse in young healthy individuals. An early index of autoimmunity? Lupus 18 436-440
8. S Stavrakis, X Yu, E Patterson, et al. (2009) Activating autoantibodies to the beta-1 adrenergic and m2 muscarinic receptors facilitate atrial fibrillation in patients with Graves' hyperthyroidism. J Am Coll Cardiol 54 1309-1316
9. CT Sawin, A Geller, PA Wolf, et al. (1994) Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 331 1249-1252
10. AR Cappola, LP Fried, AM Arnold, et al. (2006) Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 295 1033-1041
11. H Nakazawa, DA Lythall, J Noh, et al. (2000) Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation. Eur Heart J 21 327-333
12. JE Silva (2006) Thermogenic mechanisms and their hormonal regulation. Physiol Rev 86 435-464
13. EA Palmieri, S Fazio, V Palmieri, et al. (2004) Myocardial contractility and total arterial stiffness in patients with overt hyperthyroidism: acute effects of beta1-adrenergic blockade. Eur J Endocrinol 150 757-762
14. SD Carvalho-Bianco, B Kim, JW Harney, et al. (2004) Chronic cardiac-specific thyrotoxicosis increases myocardial beta-adrenergic responsiveness. Mol Endocrinol 18 1840-1849
15. K Ojamaa, I Klein, A Sabet and SF Steinberg (2000) Changes in adenylyl cyclase isoforms as a mechanism for thyroid hormone modulation of cardiac beta-adrenergic receptor responsiveness. Metabolism 49 275-279
16. M Wakasugi, R Wakao, M Tawata, et al. (1994) Change in bone mineral density in patients with hyperthyroidism after attainment of euthyroidism by dual energy X-ray absorptiometry. Thyroid 4 179-182
17. GR Mundy, JL Shapiro, JG Bandelin, et al. (1976) Direct stimulation of bone resorption by thyroid hormones. J Clin Invest 58 529-534
18. GR Williams (2013) Thyroid hormone actions in cartilage and bone. Eur Thyroid J 2 3-13
19. M Marino, G Barbesino, A Pinchera, et al. (2000) Increased frequency of euthyroid ophthalmopathy in patients with Graves' disease associated with myasthenia gravis. Thyroid 10 799-802
20. HK Mohan, AM Groves, I Fogelman and SE Clarke (2004) Thyroid hormone and parathyroid hormone competing to maintain calcium levels in the presence of vitamin D deficiency. Thyroid 14 789-791
21. A Wojcicka, JH Bassett and GR Williams (2013) Mechanisms of action of thyroid hormones in the skeleton. Biochim Biophys Acta 1830 3979-3986
22. M Zaidi, TF Davies, A Zallone, et al. (2009) Thyroid-stimulating hormone, thyroid hormones, and bone loss. Curr Osteoporos Rep 7 47-52
23. CY Yu Wai Man, PF Chinnery and PG Griffiths (2005) Extraocular muscles have fundamentally distinct properties that make them selectively vulnerable to certain disorders. Neuromuscul Disord 15 17-23
24. VR Kodali, B Jeffcote and RB Clague (1999) Thyrotoxic periodic paralysis: a case report and review of the literature. J Emerg Med 17 43-45
25. MR Dias Da Silva, JM Cerutti, LA Arnaldi and RM Maciel (2002) A mutation in the KCNE3 potassium channel gene is associated with susceptibility to thyrotoxic hypokalemic periodic paralysis. J Clin Endocrinol Metab 87 4881-4884
26. M Wakasugi, R Wakao, M Tawata, et al. (1993) Bone mineral density in patients with hyperthyroidism measured by dual energy X-ray absorptiometry. Clin Endocrinol (Oxf) 38 283-286
27. E Abe, RC Marians, W Yu, et al. (2003) TSH is a negative regulator of skeletal remodeling. Cell 115 151-162
28. R Baliram, L Sun, J Cao, et al. (2012) Hyperthyroid-associated osteoporosis is exacerbated by the loss of TSH signaling. J Clin Invest 122 3737-3741
29. B Wejda, G Hintze, B Katschinski, et al. (1995) Hip fractures and the thyroid: a case-control study. J Intern Med 237 241-247
30. J Faber and AM Galloe (1994) Changes in bone mass during prolonged subclinical hyperthyroidism due to l-thyroxine treatment: a meta-analysis. Eur J Endocrinol 130 350-356
31. DC Bauer, B Ettinger, MC Nevitt and KL Stone (2001) Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 134 561-568
32. M Dalla Costa, FA Mangano and C Betterle (Epub 2014 Aug 23) Thymic hyperplasia in patients with Graves' disease. J Endocrinol Invest
33. V Godart, B Weynand, E Coche, et al. (2005) Intense 18-fluorodeoxyglucose uptake by the thymus on PET scan does not necessarily herald recurrence of thyroid carcinoma. J Endocrinol Invest 28 1024-1028
34. C Erem, HO Ersoz, SS Karti, et al. (2002) Blood coagulation and fibrinolysis in patients with hyperthyroidism. J Endocrinol Invest 25 345-350
35. D Kurnik, R Loebstein, Z Farfel, et al. (2004) Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland. Medicine (Baltimore) 83 107-113
36. M Taniyama, K Honma and Y Ban (1993) Urinary cortisol metabolites in the assessment of peripheral thyroid hormone action: application for diagnosis of resistance to thyroid hormone. Thyroid 3 229-233
37. A Stagnaro-Green, SH Roman, RH Cobin, et al. (1990) Detection of at-risk pregnancy by means of highly sensitive assays for thyroid autoantibodies. JAMA 264 1422-1425
38. A Stagnaro-Green and D Glinoer (2004) Thyroid autoimmunity and the risk of miscarriage. Best Pract Res Clin Endocrinol Metab 18 167-181
39. A Stagnaro-Green and E Pearce (2012) Thyroid disorders in pregnancy. Nat Rev Endocrinol 8 650-658
40. AW Meikle (2004) The interrelationships between thyroid dysfunction and hypogonadism in men and boys. Thyroid 14(Suppl 1), S17-S25
41. N Tagawa, T Takano, S Fukata, et al. (2001) Serum concentration of androstenediol and androstenediol sulfate in patients with hyperthyroidism and hypothyroidism. Endocr J 48 345-354
42. CH Parry (1825) Disease of the heart: enlargement of the thyroid gland in connection with enlargement or palpitation of the heart. Collections From the Unpublished Medical Writings of the Late Caleb Hillier Parry London: Underwoods, Fleet Street 111-125
43. AP Weetman (2003) Grave's disease 1835-2002. Horm Res 59(Suppl 1), 114-118
44. CA von Basedow (1840) Exophthalmos durch Hypertrophie des Zellgewebes in der Augenhöhle. Wochensch Ges Heilk 6 197-204
45. RJ Graves (1842) Clinical Lectures, Lecture XII. Philadelphia: Barrington & Haswell
46. DD Adams (1958) The presence of an abnormal thyroid-stimulating hormone in the serum of some thyrotoxic patients. J Clin Endocrinol Metab 18 699-712
47. DD Adams (1975) The pathogenesis of thyrotoxicosis the discovery of LATS. N Z Med J 81 15-17
48. TF Davies, T Ando, RY Lin, et al. (2005) Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J Clin Invest 115 1972-1983
49. SA Morshed, R Latif and TF Davies (2009) Characterization of thyrotropin receptor antibody-induced signaling cascades. Endocrinology 150 519-529
50. A Martin, M Valentine, P Unger, et al. (1994) Engraftment of human lymphocytes and thyroid tissue into Scid and Rag2-deficient mice: absent progression of lymphocytic infiltration. J Clin Endocrinol Metab 79 716-723
51. Y Hiromatsu, T Hoshino, H Yagita, et al. (1999) Functional Fas ligand expression in thyrocytes from patients with Graves' disease. J Clin Endocrinol Metab 84 2896-2902
52. JG Hollowell, NW Staehling, WD Flanders, et al. (2002) Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 87 489-499
53. MPJ Vanderpump, WMG Tunbridge, JM French, et al. (1995) The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey. Clin Endocrinol (Oxf) 43 55-68
54. A Carle, IB Pedersen, N Knudsen, et al. (2011) Epidemiology of subtypes of hyperthyroidism in Denmark: a population-based study. Eur J Endocrinol 164 801-809
55. N Shimojo, Y Kohno, K Yamaguchi, et al. (1996) Induction of Graves-like disease in mice by immunization with fibroblasts transfected with the thyrotropin receptor and a class II molecule. Proc Natl Acad Sci U S A 93 11074-11079
56. M Kita, L Ahmad, RC Marians, et al. (1999) Regulation and transfer of a murine model of thyrotropin receptor antibody mediated Graves' disease. Endocrinology 140 1392-1398
57. T Ando, M Imaizumi, P Graves, et al. (2003) Induction of thyroid-stimulating hormone receptor autoimmunity in hamsters. Endocrinology 144 671-680
58. Y Nagayama, M Kita-Furuyama, T Ando, et al. (2002) A novel murine model of Graves' hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J Immunol 168 2789-2794
59. J Sanders, DY Chirgadze, P Sanders, et al. (2007) Crystal structure of the TSH receptor in complex with a thyroid-stimulating autoantibody. Thyroid 17 395-410
60. R Latif, A Teixeira, K Michalek, et al. (2012) Antibody protection reveals extended epitopes on the human TSH receptor. PLoS One 7 e44669
61. DD Adams and HD Purves (1956) Abnormal responses in the assay of thyrotropin. Proc Univ Otago Med Sch 34 11-12
62. Z Kraiem, N Lahat, B Glaser, et al. (1987) Thyrotropin receptor blocking antibodies: incidence, characterization and in-vitro synthesis. Clin Endocrinol (Oxf) 27 409-421
63. DD Adams, FN Fastier, JB Howie, et al. (1974) Stimulation of the human thyroid by infusions of plasma containing LATS protector. J Clin Endocrinol Metab 39 826-832
64. DS Munro, SM Dirmikis, H Humphries, et al. (1978) The role of thyroid-stimulating immunoglobulins of Graves' disease in neonatal thyrotoxicosis. Br J Obstet Gynaecol 85 837-843
65. M Zakarija and JM McKenzie (1983) Pregnancy-associated changes in thyroid-stimulating antibody of Graves' disease and the relationship to neonatal hyperthyroidism. J Clin Endocrinol Metab 57 1036-1040
66. MJ Zakarija (1983) Immunochemical characterization of the thyroid-stimulating antibody (TSab) of Graves' disease: evidence for restricted heterogeneity. J Clin Lab Immunol 10 77-85
67. AP Weetman, ME Yateman, PA Ealey, et al. (1990) Thyroid-stimulating antibody activity between different immunoglobulin G subclasses. J Clin Invest 86 723-727
68. R Tozzoli, M Bagnasco, D Giavarina and N Bizzaro (2012) TSH receptor autoantibody immunoassay in patients with Graves' disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis. Autoimmun Rev 12 107-113
69. TF Davies, PP Yeo, DC Evered, et al. (1977) Value of thyroid-stimulating-antibody determinations in predicting short-term thyrotoxic relapse in Graves' disease. Lancet 1 1181-1182
70. TF Davies, E Roti, LE Braverman and LJ DeGroot (1998) Thyroid controversy—stimulating antibodies. J Clin Endocrinol Metab 83(11), 3777-3785
71. WA Mackenzie, AE Schwartz, EW Friedman and TF Davies (1987) Intrathyroidal T cell clones from patients with autoimmune thyroid disease. J Clin Endocrinol Metab 64 818-824
72. CM Dayan, M Londei, AE Corcoran, et al. (1991) Autoantigen recognition by thyroid-infiltrating T cells in Graves disease. Proc Natl Acad Sci U S A 88 7415-7419
73. TF Davies, A Martin, ES Concepcion, et al. (1991) Evidence of limited variability of antigen receptors on intrathyroidal T cells in autoimmune thyroid disease. N Engl J Med 325 238-244
74. B Grubeck Loebenstein, M Turner, K Pirich, et al. (1990) CD4+ T-cell clones from autoimmune thyroid tissue cannot be classified according to their lymphokine production. Scand J Immunol 32 433-440
75. B Zha, X Huang, J Lin, et al. (2014) Distribution of lymphocyte subpopulations in thyroid glands of human autoimmune thyroid disease. J Clin Lab Anal 28 249-254
76. D Valmori, A Merlo, NE Souleimanian, et al. (2005) A peripheral circulating compartment of natural naive CD4 Tregs. J Clin Invest 115 1953-1962
77. JB Wing and S Sakaguchi (2014) Foxp3(+) T(reg) cells in humoral immunity. Int Immunol 26 61-69
78. AB Glick, A Wodzinski, P Fu, et al. (2013) Impairment of regulatory T-cell function in autoimmune thyroid disease. Thyroid 23 871-878
79. SA Morshed, R Latif and TF Davies (2012) Delineating the autoimmune mechanisms in Graves' disease. Immunol Res 54 191-203
80. HS Li and G Carayanniotis (2005) Detection of thyroglobulin mRNA as truncated isoform(s) in mouse thymus. Immunology 115 85-89
81. M Murakami, Y Hosoi, T Negishi, et al. (1996) Thymic hyperplasia in patients with Graves' disease. Identification of thyrotropin receptors in human thymus. J Clin Invest 98 2228-2234
82. M Stefan, C Wei, A Lombardi, et al. (2014) Genetic-epigenetic dysregulation of thymic TSH receptor gene expression triggers thyroid autoimmunity. Proc Natl Acad Sci U S A 111 12562-12567
83. N Akeno, EP Smith, M Stefan, et al. (2011) IFN-alpha mediates the development of autoimmunity both by direct tissue toxicity and through immune cell recruitment mechanisms. J Immunol 186 4693-4706
84. JT Blackard, L Kong, AK Huber and Y Tomer (2013) Hepatitis C virus infection of a thyroid cell line: implications for pathogenesis of hepatitis C virus and thyroiditis. Thyroid 23 863-870
85. Y Tomer and TF Davies (1993) Infection, thyroid disease and autoimmunity. Endocr Rev 14 107-120
86. B Rapoport, R Aalsabeh, D Aftergood and S McLachlan (2000) Elephantiasic pretibial myxedema: insight into (and a hypothesis regarding) the pathogenesis of the extrathyroidal manifestations of Graves' disease. Thyroid 10 685-692
87. D Peng, B Xu, Y Wang, et al. (2013) A high frequency of circulating th22 and th17 cells in patients with new onset Graves' disease. PLoS One 8 e68446
88. N Arata, T Ando, P Unger and TF Davies (2006) By-stander activation in autoimmune thyroiditis: studies on experimental autoimmune thyroiditis in the GFP+ fluorescent mouse. Clin Immunol 121 108-117
89. A De Riu, A Martin, M Valentine, et al. (1994) Graves' disease thyroid transplants in Scid mice: persistent selectivity in hTcR V alpha gene family use. Autoimmunity 19 271-277
90. S Wickham and DJ Carr (2004) Molecular mimicry versus bystander activation: herpetic stromal keratitis. Autoimmunity 37 393-397
91. J Srinivasappa, J Saegusa, BS Prabhakar, et al. (1986) Molecular mimicry: frequency of reactivity of monoclonal antiviral antibodies with normal tissues. J Virol 57 397-401
92. MV Haspel, T Onodrera, BS Prabhakar, et al. (1983) Multiple organ-reactive monoclonal autoantibodies. Nature 304 73-76
93. CE Hargreaves, M Grasso, CS Hampe, et al. (2013) Yersinia enterocolitica provides the link between thyroid-stimulating antibodies and their germline counterparts in Graves' disease. J Immunol 190 5373-5381
94. S Benvenga, F Guarneri, M Vaccaro, et al. (2004) Homologies between proteins of Borrelia burgdorferi and thyroid autoantigens. Thyroid 14 964-966
95. R Mirakian, LJ Hammond and GF Bottazzo (1998) Pathogenesis of thyroid autoimmunity: the Bottazzo-Feldmann hypothesis. Immunol Today 19 97-98
96. LA Piccinini, NK Goldsmith, BS Schachter and TF Davies (1988) Localization of HLA-DR alpha-chain messenger ribonucleic acid in normal and autoimmune human thyroid using in situ hybridization. J Clin Endocrinol Metab 66 1307-1315
97. R Pujol-Borrell, I Todd, M Londei, et al. (1986) Inappropriate major histocompatibility complex class II expression by thyroid follicular cells in thyroid autoimmune disease and by pancreatic beta cells in type I diabetes. Mol Biol Med 3 159-165
98. X Yin, R Sachidanandam, S Morshed, et al. (2014) mRNA-Seq reveals novel molecular mechanisms and a robust fingerprint in Graves' disease. J Clin Endocrinol Metab 99(10), E2076-E2083
99. Y Kawakami, N Kuzuya, T Watanabe, et al. (1990) Induction of experimental thyroiditis in mice by recombinant interferon gamma administration. Acta Endocrinol (Copenh) 122 41-48
100. KD Moudgil and EE Sercarz (2005) Understanding crypticity is the key to revealing the pathogenesis of autoimmunity. Trends Immunol 26 355-359
101. A Carle, I Bulow Pedersen, N Knudsen, et al. (2013) Graves' hyperthyroidism and moderate alcohol consumption: evidence for disease prevention. Clin Endocrinol (Oxf) 79 111-119
102. AP Weetman (2011) Diseases associated with thyroid autoimmunity: explanations for the expanding spectrum. Clin Endocrinol (Oxf) 74 411-418
103. R Villanueva, DA Greenberg, TF Davies and Y Tomer (2003) Sibling recurrence risk in autoimmune thyroid disease. Thyroid 13 761-764
104. TH Brix, K Christensen, NV Holm, et al. (1998) A population-based study of Graves' disease in Danish twins. Clin Endocrinol (Oxf) 48 397-400
105. Y Tomer, DA Greenberg, G Barbesino, et al. (2001) CTLA-4 and not CD28 is a susceptibility gene for thyroid autoantibody production. J Clin Endocrinol Metab 86 1687-1693
106. NR Farid and JC Bear (1981) The human major histocompatibility complex and endocrine disease. Endocr Rev 2 50-86
107. G Barbesino, Y Tomer, ES Concepcion, et al. (1998) Linkage analysis of candidate genes in autoimmune thyroid disease: 1. Selected immunoregulatory genes. J Clin Endocrinol Metab 83 1580-1584
108. Y Ban, ES Concepcion, R Villanueva, et al. (2004) Analysis of immune regulatory genes in familial and sporadic Graves' disease. J Clin Endocrinol Metab 89 4562-4568
109. X Chu, CM Pan, SX Zhao, et al. (2011) A genome-wide association study identifies two new risk loci for Graves' disease. Nat Genet 43 897-901
110. SX Zhao, LQ Xue, W Liu, et al. (2013) Robust evidence for five new Graves' disease risk loci from a staged genome-wide association analysis. Hum Mol Genet 22 3347-3362
111. Y Tomer and D Greenberg (2004) The thyroglobulin gene as the first thyroid-specific susceptibility gene for autoimmune thyroid disease. Trends Mol Med 10 306-308
112. X Yin, R Latif, R Bahn, et al. (2008) Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy. Thyroid 18 1201-1206
113. OJ Brand, JC Barrett, MJ Simmonds, et al. (2009) Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves' disease. Hum Mol Genet 18 1704-1713
114. M Samarkos and G Vaiopoulos (2005) The role of infections in the pathogenesis of autoimmune diseases. Curr Drug Targets Inflamm Allergy 4 99-103
115. JK Olson, JL Croxford and SD Miller (2001) Virus-induced autoimmunity: potential role of viruses in initiation, perpetuation, and progression of T-cell-mediated autoimmune disease. Viral Immunol 14 227-250
116. F Menconi, A Hasham and Y Tomer (2011) Environmental triggers of thyroiditis: hepatitis C and interferon-alpha. J Endocrinol Invest 34 78-84
117. R Vita, D Lapa, F Trimarchi and S Benvenga (2015) Stress triggers the onset and the recurrences of hyperthyroidism in patients with Graves' disease. Endocrine 48(1), 254-263
118. G Effraimidis, JG Tijssen, JF Brosschot and WM Wiersinga (2012) Involvement of stress in the pathogenesis of autoimmune thyroid disease: a prospective study. Psychoneuroendocrinology 37(8), 1191-1198
119. M Irwin (1994) Stress-induced immune suppression: role of brain corticotropin releasing hormone and autonomic nervous system mechanisms. Adv Neuroimmunol 4 29-47
120. GD Marshall (2004) Neuroendocrine mechanisms of immune dysregulation: applications to allergy and asthma. Ann Allergy Asthma Immunol 93 S11-S17
121. G Falgarone, HM Heshmati, R Cohen and G Reach (2013) Mechanisms in endocrinology. Role of emotional stress in the pathophysiology of Graves' disease. Eur J Endocrinol 168 R13-R18
122. N Amino, H Tada, Y Hidaka, et al. (1999) Therapeutic controversy: screening for postpartum thyroiditis. J Clin Endocrinol Metab 84 1813-1821
123. B Polese, V Gridelet, E Araklioti, et al. (2014) The endocrine milieu and CD4 T-lymphocyte polarization during pregnancy. Front Endocrinol (Lausanne) 5 106
124. AS Ansar, PR Young and WJ Penhale (1986) Beneficial effect of testosterone in the treatment of chronic autoimmune thyroiditis in rats. J Immunol 136 143-147
125. N Gleicher and DH Barad (2007) Gender as risk factor for autoimmune diseases. J Autoimmun 28 1-6
126. Y Ban, T Tozaki, T Tobe, et al. (2007) The regulatory T cell gene FOXP3 and genetic susceptibility to thyroid autoimmunity: an association analysis in Caucasian and Japanese cohorts. J Autoimmun 28 201-207
127. JC Chow, Z Yen, SM Ziesche and CJ Brown (2005) Silencing of the mammalian X chromosome. Annu Rev Genomics Hum Genet 6 69-92
128. TH Brix, GP Knudsen, M Kristiansen, et al. (2005) High frequency of skewed X-chromosome inactivation in females with autoimmune thyroid disease: a possible explanation for the female predisposition to thyroid autoimmunity. J Clin Endocrinol Metab 90 5949-5953
129. X Yin, R Latif, Y Tomer and TF Davies (2007) Thyroid epigenetics: X chromosome inactivation in patients with autoimmune thyroid disease. Ann N Y Acad Sci 1110 193-200
130. JH Mestman (2012) Hyperthyroidism in pregnancy. Curr Opin Endocrinol Diabetes Obes 19 394-401
131. JH Mestman (1998) Hyperthyroidism in pregnancy. Endocrinol Metab Clin North Am 27 127-149
132. GW Chan and SJ Mandel (2007) Therapy insight: management of Graves' disease during pregnancy. Nat Clin Pract Endocrinol Metab 3 470-478
133. J Anselmo, D Cao, T Karrison, et al. (2004) Fetal loss associated with excess thyroid hormone exposure. JAMA 292 691-695
134. VR Aluvihare, M Kallikourdis and AG Betz (2005) Tolerance, suppression and the fetal allograft. J Mol Med 83 88-96
135. A Stagnaro-Green, SH Roman, RH Cobin, et al. (1992) A prospective study of lymphocyte-initiated immunosuppression in normal pregnancy: evidence of a T-cell etiology for postpartum thyroid dysfunction. J Clin Endocrinol Metab 74 645-653
136. R Jansson, PA Dahlberg, B Winsa, et al. (1987) The postpartum period constitutes an important risk for the development of clinical Graves' disease in young women. Acta Endocrinol (Copenh) 116(3), 321-325
137. M Rotondi, C Cappelli, B Pirali, et al. (2008) The effect of pregnancy on subsequent relapse from Graves' disease after a successful course of antithyroid drug therapy. J Clin Endocrinol Metab 93 3985-3988
138. S Basaria and DS Cooper (2005) Amiodarone and the thyroid. Am J Med 118 706-714
139. Y Tomer, JT Blackard and N Akeno (2007) Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am 36 1051-1066. x-xi
140. L DeGroot (1993) Effects of irradiation on the thyroid gland. Endocrinol Metab Clin North Am 22 607-615
141. D Huysmans, A Hermus, M Edelbrook, et al. (1997) Autoimmune hyperthyroidism occurring late after radioiodine treatment for volume reduction of large multinodular goiters. Thyroid 7 535-539
142. F Pacini, T Vorontsova, E Molinaro, et al. (1998) Prevalence of thyroid autoantibodies in children and adolescents from Belarus exposed to the Chernobyl radioactive fallout. Lancet 352 763-766
143. F Vermiglio, MG Castagna, E Volnova, et al. (1999) Post-Chernobyl increased prevalence of humoral thyroid autoimmunity in children and adolescents from a moderately iodine-deficient area in Russia. Thyroid 9 781-786
144. EV Vykhovanets, VP Chernyshov, I Slukvin, et al. (1997) 131-I dose-dependent thyroid autoimmune disorders in children living around Chernobyl. Clin Immunol Immunopathol 84 251-259
145. AM McGregor, MM Petersen, R Capifferi, et al. (1979) A prospective study of the effects of radioiodine therapy on thyroid-stimulating antibody synthesis in Grave's disease [proceedings]. J Endocrinol 81(2), 114P-115P
146. P Laurberg, G Wallin, L Tallstedt, et al. (2008) TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 158 69-75
147. L Bartalena, C Marcocci, ML Tanda, et al. (2005) An update on medical management of Graves' ophthalmopathy. J Endocrinol Invest 28 469-478
148. BS Prabhakar, RS Bahn and TJ Smith (2003) Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev 24 802-835
149. SE Feldon, DJ Park, CW O'Loughlin, et al. (2005) Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves' ophthalmopathy. Invest Ophthalmol Vis Sci 46 3913-3921
150. B Grubeck-Loebenstein, K Trieb, W Holter, et al. (1993) Retrobulbar T cells from patients with Graves' ophthalmopathy are CD8+ and specifically autologous fibroblasts. J Clin Invest 93 2738-2743
151. S Mori, N Yoshikawa, T Tokoro, et al. (1996) Studies of retroorbital tissue xenografts from patients with Graves' ophthalmopathy in severe combined immunodeficient (SCID) mice: detection of thyroid-stimulating antibody. Thyroid 6 275-281
152. RS Douglas, NF Afifiyan, CJ Hwang, et al. (2010) Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 95(1), 430-438
153. DR Weightman, P Perros, IH Sherif and P Kendall-Taylor (1993) Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity 16 251-257
154. TJ Smith, CC Tsai, MJ Shih, et al. (2008) Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid 18 983-988
155. WB Minich, N Dehina, T Welsink, et al. (2013) Autoantibodies to the IGF1 receptor in Graves' orbitopathy. J Clin Endocrinol Metab 98 752-760
156. WM Wiersinga (2011) Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors? J Clin Endocrinol Metab 96 2386-2394
157. AG Gianoukakis, RS Douglas, CS King, et al. (2006) IgG from patients with Graves' disease induces IL-16 and RANTES expression in cultured human thyrocytes: a putative mechanism for T cell infiltration of the thyroid in autoimmune disease. Endocrinology 147(4), 1941-1949
158. R Villanueva, AM Inzerillo, Y Tomer, et al. (2000) Limited genetic susceptibility to severe Graves' ophthalmopathy: no role for CTLA-4 but evidence for an environmental etiology. Thyroid 10(9), 791-798
159. X Yin, R Latif, R Bahn and TF Davies (2012) Genetic profiling in Graves' disease: further evidence for lack of a distinct genetic contribution to Graves' ophthalmopathy. Thyroid 22 730-736
160. B Shine, P Fells, OM Edwards and AP Weetman (1990) Association between Graves' ophthalmopathy and smoking. Lancet 335 1261-1263
161. WM Wiersinga (2013) Smoking and thyroid. Clin Endocrinol (Oxf) 79 145-151
162. LC Wood and SH Ingbar (1979) Hypothyroidism as a late sequela in patients with Graves' disease treated with antithyroid agents. J Clin Invest 64 1429-1436
163. P Laurberg, B Nygaard, S Andersen, et al. (2014) Association between TSH-receptor autoimmunity, hyperthyroidism, goitre, and orbitopathy in 208 patients included in the remission induction and sustenance in Graves' disease study. J Thyroid Res 2014 165487
164. AW Kung, CC Yau and A Cheng (1994) The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole. J Clin Endocrinol Metab 79 542-546
165. ML Tanda, E Piantanida, L Liparulo, et al. (2013) Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center. J Clin Endocrinol Metab 98(4), 1443-1449
166. F Traisk, L Tallstedt, M Abraham-Nordling, et al. (2009) Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 94 3700-3707
167. AK Eckstein, M Plicht, H Lax, et al. (2006) Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91 3464-3470
168. MN Stan and RS Bahn (2010) Risk factors for development or deterioration of Graves' ophthalmopathy. Thyroid 20 777-783
169. FF Rundle and CW Wilson (1945) Development and course of exophthalmos and ophthalmoplegia in Graves' disease with special reference to the effect of thyroidectomy. Clin Sci 5 177-194
170. RS Bahn (2010) Graves' ophthalmopathy. N Engl J Med 362 726-738
171. MN Stan, JA Garrity and RS Bahn (2012) The evaluation and treatment of Graves ophthalmopathy. Med Clin North Am 96 311-328
172. D McKeag, C Lane, JH Lazarus, et al. (2007) Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey. Br J Ophthalmol 91 455-458
173. GJ Ben Simon, HM Syed, R Douglas, et al. (2006) Clinical manifestations and treatment outcome of optic neuropathy in thyroid-related orbitopathy. Ophthalmic Surg Lasers Imaging 37(4), 284-290
174. L Bartalena, L Baldeschi, A Dickinson, et al. (2008) Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158(3), 273-285
175. V Fatourechi (2012) Thyroid dermopathy and acropachy. Best Pract Res Clin Endocrinol Metab 26 553-565
176. BR Smith, J Bolton, S Young, et al. (2004) A new assay for thyrotropin receptor autoantibodies. Thyroid 14 830-835
177. JJ Leschik, T Diana, PD Olivo, et al. (2013) Analytical performance and clinical utility of a bioassay for thyroid-stimulating immunoglobulins. Am J Clin Pathol 139 192-200
178. M Schott, WB Minich, HS Willenberg, et al. (2005) Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease. Horm Metab Res 37 741-744
179. PA Singer, DS Cooper, E Levy, et al. (1995) Treatment guidelines for patients with hyperthyroidism and hypothyroidism. JAMA 273 808-812
180. DS Cooper (2005) Antithyroid drugs. N Engl J Med 352 905-917
181. J Abuid and PR Larsen (1974) Triiodothyronine and thyroxine in hyperthyroidism. Comparison of the acute changes during therapy with antithyroid agents. J Clin Invest 54 201-208
182. AL Maia, BW Kim, SA Huang, et al. (2005) Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J Clin Invest 115 2524-2533
183. P Laurberg, H Vestergaard, S Nielsen, et al. (2007) Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. J Clin Endocrinol Metab 92 2149-2156
184. Y Okamura, C Shigemasa and T Tatsuhara (1986) Pharmacokinetics of methimazole in normal subjects and hyperthyroid patients. Endocrinol Jpn 33 605-615
185. AP Weetman (1994) The immunomodulatory effects of antithyroid drugs. Thyroid 4 145-146
186. G Stassi, A Zeuner, D Di Liberto, et al. (2001) Fas-FasL in Hashimoto's thyroiditis. J Clin Immunol 21 19-23
187. P De Vito, S Incerpi, JZ Pedersen, et al. (2011) Thyroid hormones as modulators of immune activities at the cellular level. Thyroid 21 879-890
188. L Harper, L Chin, J Daykin, et al. (2004) Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease. Clin Endocrinol (Oxf) 60 671-675
189. SA Rivkees and DR Mattison (2009) Propylthiouracil (PTU) hepatoxicity in children and recommendations for discontinuation of use. Int J Pediatr Endocrinol 2009 132041
190. DS Cooper and SA Rivkees (2009) Putting propylthiouracil in perspective. J Clin Endocrinol Metab 94 1881-1882
191. KA Woeber (2002) Methimazole-induced hepatotoxicity. Endocr Pract 8 222-224
192. SA Rivkees (2010) 63 years and 715 days to the “boxed warning”: unmasking of the propylthiouracil problem. Int J Pediatr Endocrinol 2010 658267
193. RS Bahn, HS Burch, DS Cooper, et al. (2009) The role of propylthiouracil in the management of Graves' disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 19 673-674
194. RS Bahn Chair, HB Burch, DS Cooper, et al. (2011) Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21 593-646
195. H Nakamura, JY Noh, K Itoh, et al. (2007) Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 92 2157-2162
196. G Benker, D Reinwein, G Kahaly, et al. (1998) Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs. Clin Endocrinol (Oxf) 49 451-457
197. V Sundaresh, JP Brito, Z Wang, et al. (2013) Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab 98 3671-3677
198. A Allahabadia, J Daykin, RL Holder, et al. (2000) Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab 85 1038-1042
199. GA Brent (2008) Clinical practice. Graves' disease. N Engl J Med 358 2594-2605
200. F Bogazzi, L Bartalena, L Tomisti, et al. (2008) Potassium perchlorate only temporarily restores euthyroidism in patients with amiodarone-induced hypothyroidism who continue amiodarone therapy. J Endocrinol Invest 31 515-519
201. CH Emerson, AJ Anderson, WJ Howard and RD Utiger (1975) Serum thyroxine and triiodothyronine concentrations during iodide treatment of hyperthyroidism. J Clin Endocrinol Metab 40 33-36
202. M Chiha, S Samarasinghe and AS Kabaker (2015) Thyroid storm: an updated review. J Intensive Care Med 30(3), 131-140
203. JD Myers, ES Brannon and BC Holland (1950) A correlative study of the cardiac output and the hepatic circulation in hyperthyroidism. J Clin Invest 29 1069-1077
204. JA Sosa, HM Bowman, JM Tielsch, et al. (1998) The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 228 320-330
205. F Rulli, V Ambrogi, G Dionigi, et al. (2014) Meta-analysis of recurrent laryngeal nerve injury in thyroid surgery with or without intraoperative nerve monitoring. Acta Otorhinolaryngol Ital 34 223-229
206. DC Chang, MH Wheeler, JP Woodcock, et al. (1987) The effect of preoperative Lugol's iodine on thyroid blood flow in patients with Graves' hyperthyroidism. Surgery 102 1055-1061
207. Y Erbil, Y Ozluk, M Giris, et al. (2007) Effect of lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves' disease. J Clin Endocrinol Metab 92 2182-2189
208. AD Toft, WJ Irvine, I Sinclair, et al. (1978) Thyroid function after surgical treatment of thyrotoxicosis. A report of 100 cases treated with propranolol before operation. N Engl J Med 298 643-647
209. JA Franklyn, P Maisonneuve, M Sheppard, et al. (1999) Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 353 2111-2115
210. K Boelaert, P Maisonneuve, B Torlinska and JA Franklyn (2013) Comparison of mortality in hyperthyroidism during periods of treatment with thionamides and after radioiodine. J Clin Endocrinol Metab 98 1869-1882
211. TD Cheetham, P Wraight, IA Hughes and ND Barnes (1998) Radioiodine treatment of Graves' disease in young people. Horm Res 49 258-262
212. GE Berg, EH Nystrom, L Jacobsson, et al. (1998) Radioiodine treatment of hyperthyroidism in a pregnant women. J Nucl Med 39 357-361
213. N Nakazato, K Yoshida, K Mori, et al. (1999) Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease. Thyroid 9 775-779
214. S Razvi, A Basu, EA McIntyre, et al. (2004) Low failure rate of fixed administered activity of 400 MBq 131I with pre-treatment with carbimazole for thyrotoxicosis: the Gateshead Protocol. Nucl Med Commun 25 675-682
215. RD Harvey, RA Metclafe, C Morteo, et al. (1995) Acute pre-tibial myxedema following radioiodine therapy for thyrotoxic Graves' disease. Clin Endocrinol (Oxf) 42 657-660
216. GE Krassas, A Stafilidou and KG Boboridis (2010) Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids. Clin Endocrinol (Oxf) 72 853-855
217. V Fatourechi (2005) Pretibial myxedema: pathophysiology and treatment options. Am J Clin Dermatol 6 295-309
218. C Heyes, R Nolan, M Leahy and K Gebauer (2012) Treatment-resistant elephantiasic thyroid dermopathy responding to rituximab and plasmapheresis. Australas J Dermatol 53 e1-e4
219. M Salvi, G Vannucchi, I Campi and P Beck-Peccoz (2009) Rituximab in the treatment of thyroid eye disease: science fiction? Orbit 28 251-255
220. MA Walter, M Briel, M Christ-Crain, et al. (2007) Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ 334 514
221. CA Gorman (1999) Radioiodine and pregnancy. Thyroid 9 721-726
222. O Sabri, M Zimny, M Schreckenberger, et al. (1999) Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy. Thyroid 9 1181-1188
223. PW Dickman, LE Holm, G Lundell, et al. (2003) Thyroid cancer risk after thyroid examination with 131I: a population-based cohort study in Sweden. Int J Cancer 106 580-587
224. KB Moysich, RJ Menezes and AM Michalek (2002) Chernobyl-related ionising radiation exposure and cancer risk: an epidemiological review. Lancet Oncol 3 269-279
225. Y Nikiforov, C Heffess, A Korzenko, et al. (1995) Characteristics of follicular tumors and nonneoplastic thyroid lesions in children and adolescents exposed to radiation as a result of the Chernobyl disaster. Cancer 76 900
226. Y Gavrilin, V Khrouch, S Shinkarev, et al. (2004) Individual thyroid dose estimation for a case-control study of Chernobyl-related thyroid cancer among children of Belarus: part I. I-131, short-lived radioiodines (I-132, I-133, I-135), and short-lived radiotelluriums (Te-131M and Te-132). Health Phys 86 565-585
227. JA Franklyn, MC Sheppard and P Maisonneuve (2005) Thyroid function and mortality in patients treated for hyperthyroidism. JAMA 294 71-80
228. TH Collet, J Gussekloo, DC Bauer, et al. (2012) Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 172 799-809
229. WD Leslie, L Ward, EA Salamon, et al. (2003) A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab 88 978-983
230. S Metso, P Jaatinen, H Huhtala, et al. (2004) Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol (Oxf) 61 641-648
231. AM McGregor, MM Petersen, R Capiferri, et al. (1979) Effects of radioiodine on thyrotrophin binding inhibiting immunoglobulins in Graves' disease. Clin Endocrinol (Oxf) 11 437-444
232. L Bartalena, C Marcocci, F Bogazzi, et al. (1989) Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 321 1349-1352
233. L Tallestedt, G Lundell, O Torring, et al. (1992) Occurrence of ophthalmopathy after treatment for Graves' disease. N Engl J Med 326 1733-1738
234. CA Gorman (1995) Therapeutic controversies. Radioiodine therapy does not aggravate Graves' ophthalmopathy. J Clin Endocrinol Metab 80 340-342
235. MN Stan, JM Durski, JP Brito, et al. (2013) Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment. Thyroid 23 620-625
236. L Bartalena (2014) Steroid prophylaxis after radioiodine treatment for Graves' hyperthyroidism: selective or universal? Thyroid 24(10), 1441-1442
237. AM Sawka, L Thabane, L Parlea, et al. (2009) Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 19 451-457
238. J Dale, J Daykin, R Holder, et al. (2001) Weight gain following treatment of hyperthyroidism. Clin Endocrinol (Oxf) 55 233-239
239. WM Wiersinga and MF Prummel (2002) Graves' ophthalmopathy: a rational approach to treatment. Trends Endocrinol Metab 13 280-287
240. J Jarhult, C Rudberg, E Larsson, et al. (2005) Graves' disease with moderate-severe endocrine ophthalmopathy-long term results of a prospective, randomized study of total or subtotal thyroid resection. Thyroid 15 1157-1164
241. F Menconi, M Marino, A Pinchera, et al. (2007) Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab 92 1653-1658
242. L Bartalena and ML Tanda (2009) Clinical practice. Graves' ophthalmopathy. N Engl J Med 360 994-1001
243. S Aktaran, E Akarsu, I Erbagci, et al. (2007) Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy. Int J Clin Pract 61 45-51
244. S Zang, KA Ponto and GJ Kahaly (2011) Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 96 320-332
245. M Marino, E Morabito, MR Brunetto, et al. (2004) Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy. Thyroid 14 403-406
246. ML Tanda, E Piantanida and L Bartalena (2012) Treating Graves' orbitopathy: where are we? Endocrine 41 167-168
247. G Vannucchi, D Covelli, I Campi, et al. (2014) The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor. Eur J Endocrinol 170 55-61
248. P Perros and GE Krassas (2002) Orbital irradiation for thyroid-associated orbitopathy: conventional dose, low dose or no dose? Clin Endocrinol (Oxf) 56 689-691
249. CA Gorman, JA Garrity, V Fatourechi, et al. (2001) A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology 108 1523-1534
250. MF Prummel, CB Terwee, MN Gerding, et al. (2004) A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. J Clin Endocrinol Metab 89 15-20
251. PR Boulos and I Hardy (2004) Thyroid-associated orbitopathy: a clinicopathologic and therapeutic review. Curr Opin Ophthalmol 15 389-400
252. MP Mourits, L Koornneef, WM Wiersinga, et al. (1990) Orbital decompression for Graves' ophthalmopathy by inferomedial, by inferomedial plus lateral, and by coronal approach. Ophthalmology 97 636-641
253. L Bartalena (2014) Commentary: rituximab, adalimumab, etanercept, tocilizumab—are biologics the future for Graves' orbitopathy? Ophthal Plast Reconstr Surg 30 420-423
254. AL Mitchell, EH Gan, M Morris, et al. (2013) The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves' orbitopathy. Clin Endocrinol (Oxf) 79 437-442
255. L Bartalena and V Fatourechi (2014) Extrathyroidal manifestations of Graves' disease: a 2014 update. J Endocrinol Invest 37(8), 691-700
256. T Akamizu, T Satoh, O Isozaki, et al. (2012) Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys. Thyroid 22 661-679
257. J Klubo-Gwiezdzinska and L Wartofsky (2012) Thyroid emergencies. Med Clin North Am 96 385-403
258. AC Bianco, D Salvatore, B Gereben, et al. (2002) Biochemistry, cellular and molecular biology and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 23 38-89
259. P Laurberg, J Torring and J Weeke (1985) A comparison of the effects of propylthiouracil and methimazol on circulating thyroid hormones and various measures of peripheral thyroid hormone effects in thyrotoxic patients. Acta Endocrinol (Copenh) 108 51-54
260. TF Davies, GS Taliadouros, KJ Catt and BC Nisula (1979) Assessment of urinary thyrotropin-competing activity in choriocarcinoma and thyroid disease: further evidence for human chorionic gonadotropin interacting at the thyroid cell membrane. J Clin Endocrinol Metab 49 353-357
261. TF Davies and M Platzer (1986) hCG-induced TSH receptor activation and growth acceleration in FRTL-5 thyroid cells. Endocrinology 118 2149-2151
262. Y Tomer, GK Huber and TF Davies (1992) Human chorionic gonadotropin (hCG) interacts directly with recombinant human TSH receptors. J Clin Endocrinol Metab 74 1477-1479
263. JP Grun, S Meuris, P De Nayer and D Glinoer (1997) The thyrotrophic role of human chorionic gonadotrophin (hCG) in the early stages of twin (versus single) pregnancies. Clin Endocrinol (Oxf) 46 719-725
264. TM Goodwin, M Montoro, JH Mestman, et al. (1992) The role of chorionic gonadotropin in transient hyperthyroidism of hyperemesis gravidarum. J Clin Endocrinol Metab 75 1333-1337
265. DS Cooper and P Laurberg (2013) Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol 1 238-249
266. P Rodien, C Bremont, ML Sanson, et al. (1998) Familial gestational hyperthyroidism caused by a mutant thyrotropin receptor hypersensitive to human chorionic gonadotropin. N Engl J Med 339 1823-1826
267. EJ Han, HD Song, JH Yang, et al. (2013) Thyroid dysfunction associated with administration of the long-acting gonadotropin-releasing hormone agonist. Endocrinol Metab (Seoul) 28 221-225
268. JC Galofre and TF Davies (2009) Autoimmune thyroid disease in pregnancy: a review. J Womens Health (Larchmt) 18 1847-1856
269. JH Lazarus (2005) Thyroid disease in pregnancy and childhood. Minerva Endocrinol 30 71-87
270. TF Davies (1999) The thyroid immunology of the postpartum period. Thyroid 9 675-684
271. AP Weetman (2010) Immunity, thyroid function and pregnancy: molecular mechanisms. Nat Rev Endocrinol 6 311-318
272. DA Somerset, Y Zheng, MD Kilby, et al. (2004) Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. Immunology 112 38-43
273. PC Evans, N Lambert, S Maloney, et al. (1999) Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma. Blood 93 2033-2037
274. T Lepez, M Vandewoestyne, S Hussain, et al. (2011) Fetal microchimeric cells in blood of women with an autoimmune thyroid disease. PLoS One 6 e29646
275. T Ando and TF Davies (2003) Clinical review 160: Postpartum autoimmune thyroid disease: the potential role of fetal microchimerism. J Clin Endocrinol Metab 88 2965-2971
276. JC Galofre (2012) Microchimerism in Graves' disease. J Thyroid Res 2012 724382
277. NC Lambert, PC Evans, TL Hashizumi, et al. (2000) Cutting edge: persistent fetal microchimerism in T lymphocytes is associated with HLA-DQA1*0501: implications in autoimmunity. J Immunol 164 5545-5548
278. N Amino, R Kuro, O Tanizawa, et al. (1978) Changes of serum antithyroid antibodies during and after pregnancy in autoimmune thyroid diseases. Clin Exp Immunol 31 30-37
279. FS Balucan, SA Morshed and TF Davies (2013) Thyroid autoantibodies in pregnancy: their role, regulation and clinical relevance. J Thyroid Res 2013 182472
280. VR Aluvihare, M Kallikourdis and AG Betz (2004) Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 5 266-271
281. J Abeillon-du Payrat, K Chikh, N Bossard, et al. (2014) Predictive value of maternal second-generation thyroid-binding inhibitory immunoglobulin assay for neonatal autoimmune hyperthyroidism. Eur J Endocrinol 171 451-460
282. D Luton, I Le Gac, E Vuillard, et al. (2005) Management of Graves' disease during pregnancy: the key role of fetal thyroid gland monitoring. J Clin Endocrinol Metab 90 6093-6098
283. N Amino, O Tanizawa, H Mori, et al. (1982) Aggravation of thyrotoxicosis in early pregnancy and after delivery in Graves' disease. J Clin Endocrinol Metab 55 108-112
284. JM Hershman (1999) Human chorionic gonadotropin and the thyroid: hyperemesis gravidarum and trophoblastic tumors. Thyroid 9 653-657
285. D Springer, V Bartos and T Zima (2014) Reference intervals for thyroid markers in early pregnancy determined by 7 different analytical systems. Scand J Clin Lab Invest 74 95-101
286. AS Khalid, Z Marchocki, K Hayes, et al. (2014) Establishing trimester-specific maternal thyroid function reference intervals. Ann Clin Biochem 51 277-283
287. SO LeBeau and SJ Mandel (2006) Thyroid disorders during pregnancy. Endocrinol Metab Clin North Am 35 117-136. vii
288. RG Cheron, M Kaplan, P Reed Larsen, et al. (1981) Neonatal thyroid function after propylthiouracil therapy for maternal Graves' disease. N Engl J Med 304 525-528
289. A Stagnaro-Green (2012) Optimal care of the pregnant woman with thyroid disease. J Clin Endocrinol Metab 97 2619-2622
290. M Abalovich, N Amino, LA Barbour, et al. (2007) Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 92 S1-S47
291. RH Mortimer, GR Cannell, RS Addison, et al. (1997) Methimazole and propylthiouracil equally cross the perfused human term placental lobule. J Clin Endocrinol Metab 82 3099-3102
292. S Milham Jr and W Elledge (1972) Maternal methimazole and congenital defects in children. Teratology 5 125-126
293. S Milham Jr (1985) Scalp defects in infants of mothers treated for hyperthyroidism with methimazole or carbimazole during pregnancy. Teratology 32 321
294. M Clementi, E Di Gianantonio, E Pelo, et al. (1999) Methimazole embryopathy: delineation of the phenotype. Am J Med Genet 83 43-46
295. A Stagnaro-Green, M Abalovich, E Alexander, et al. (2011) Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 21 1081-1125
296. LJ De Groot and J Mestman (2012) Detecting and treating thyroid nodules and cancer before, during, and after pregnancy: a patient's guide. J Clin Endocrinol Metab 97 37A-38A
297. A Yoshihara, J Noh, T Yamaguchi, et al. (2012) Treatment of Graves' disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab 97 2396-2403
298. SL Andersen, J Olsen, CS Wu and P Laurberg (2013) Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab 98 4373-4381
299. KL Moore, TVN Persaud and MG Torchia (2013) Human birth defects. The Developing Human: Clinically Oriented Embryology Philadelphia, PA: Saunders/Elsevier 471-501
300. VC Benavides, MK Mallela, CJ Booth, et al. (2012) Propylthiouracil is teratogenic in murine embryos. PLoS One 7 e35213
301. NR van Veenendaal, B Ulmer, MT Boskovski, et al. (2013) Embryonic exposure to propylthiouracil disrupts left-right patterning in Xenopus embryos. FASEB J 27 684-691
302. SL Andersen, J Olsen, CS Wu and P Laurberg (2014) Severity of birth defects after propylthiouracil exposure in early pregnancy. Thyroid 24(10), 1522-1540
303. P Laurberg and SL Andersen (2014) Therapy of endocrine disease: antithyroid drug use in early pregnancy and birth defects: time windows of relative safety and high risk? Eur J Endocrinol 171 R13-R20
304. N Momotani, J Noh, H Oyanagi, et al. (1986) Antithyroid drug therapy for Graves' disease during pregnancy: optimal regimen for fetal thyroid status. N Engl J Med 315 24-28
305. KP Petit and HC Nielsen (1992) Chronic in utero beta-blockade alters fetal lung development. Dev Pharmacol Ther 19 131-140
306. JG Ray, MJ Vermeulen, EA Burrows and RF Burrows (2001) Use of antihypertensive medications in pregnancy and the risk of adverse perinatal outcomes: McMaster Outcome Study of Hypertension In Pregnancy 2 (MOS HIP 2). BMC Pregnancy Childbirth 1 6
307. N Momotani, T Hisaoka, J Noh, et al. (1992) Effects of iodine on thyroid status of fetus versus mother in treatment of Graves' disease complicated by pregnancy. J Clin Endocrinol Metab 75 738-744
308. P Laurberg, C Bournaud, J Karmisholt and J Orgiazzi (2009) Management of Graves' hyperthyroidism in pregnancy: focus on both maternal and foetal thyroid function, and caution against surgical thyroidectomy in pregnancy. Eur J Endocrinol 160 1-8
309. BA Lamberg, EI Konen, K Teramo, et al. (1981) Treatment of maternal hyperthyroidism with antithyroid agents and changes in thyrotropin and thyroxine in the newborn. Acta Endocrinol (Copenh) 97 186-195
310. N Amino, H Mori, Y Iwatani, et al. (1982) High prevalence of transient post-partum thyrotoxicosis and hypothyroidism. N Engl J Med 306 849-852
311. A Stagnaro-Green (2012) Approach to the patient with postpartum thyroiditis. J Clin Endocrinol Metab 97 334-342
312. DB Rochester and TF Davies (2005) Increased risk of Graves' disease after pregnancy. Thyroid 15 1287-1290
313. JH Lazarus (2012) Pre-conception counselling in Graves' disease. Eur Thyroid J 1 24-29
314. SJ Mandel and DS Cooper (2001) The use of antithyroid drugs in pregnancy and lactation. J Clin Endocrinol Metab 86 2354-2359
315. S Karras, T Tzotzas, T Kaltsas and GE Krassas (2010) Pharmacological treatment of hyperthyroidism during lactation: review of the literature and novel data. Pediatr Endocrinol Rev 8 25-33
316. S Refetoff (2003) Resistance to thyrotropin. J Endocrinol Invest 26 770-779
317. L Duprez, J Parma, J Van Sande, et al. (1994) Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nat Genet 7 396-401
318. J Parma, L Duprez, J Van Sande, et al. (1993) Somatic mutations of the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365 649-651
319. TSH Receptor Mutation Database. http://endokrinologie.uniklinikum-leipzig.de/tsh/ University of Leipzig, Leipzig, Germany; Available at
320. L Hegedus, SJ Bonnema and FN Bennedbaek (2003) Management of simple nodular goiter: current status and future perspectives. Endocr Rev 24 102-132
321. K Krohn, D Fuhrer, Y Bayer, et al. (2005) Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr Rev 26 504-524
322. Z Kraiem, B Glaser, M Yigla, et al. (1987) Toxic multinodular goiter: a variant of autoimmune hyperthyroidism. J Clin Endocrinol Metab 65 659-664
323. B Nygaard, L Hegedus, KG Nielsen, et al. (1999) Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules. Clin Endocrinol (Oxf) 50 197-202
324. DAKC Huysmans, RMM Hermus, FHM Corstens, et al. (1994) Large, compressive, goiters treated with radioiodine. Ann Intern Med 121 757-762
325. M Tonacchera, P Agretti, V Rosellini, et al. (2000) Sporadic nonautoimmune congenital hyperthyroidism due to a strong activating mutation of the thyrotropin receptor gene. Thyroid 10 859-863
326. D Evered and R Hall (1972) Hypothyroidism. Br Med J 1 290-293
327. K Carr, DT Mcleod, G Parry and HM Thornes (1988) Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone tests using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment. Clin Endocrinol (Oxf) 28 325-333
328. GM Bell, JSA Sawers, JC Forfar, et al. (1983) The effect of minor increments in plasma thyroxine on heart rate and urinary sodium excretion. Clin Endocrinol (Oxf) 18 511-516
329. C Selmer, JB Olesen, ML Hansen, et al. (2014) Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J Clin Endocrinol Metab 99 2372-2382
330. JJ Nicholls, MJ Brassill, GR Williams and JH Bassett (2012) The skeletal consequences of thyrotoxicosis. J Endocrinol 213 209-221
331. MC Garin, AM Arnold, JS Lee, et al. (2014) Subclinical thyroid dysfunction and hip fracture and bone mineral density in older adults: the cardiovascular health study. J Clin Endocrinol Metab 99 2657-2664
332. J Faber, N Wiinberg, S Schifter and J Mehlsen (2001) Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. Eur J Endocrinol 145 391-396
333. MI Surks, E Ortiz, GH Daniels, et al. (2004) Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291 228-238
334. CT Sawin, A Geller, MM Kaplan, et al. (1991) Low serum thyrotropin (thyroid-stimulating hormone) in older persons without hyperthyroidism. Arch Intern Med 151 165-168
335. J Meyerovitch, P Rotman-Pikielny, M Sherf, et al. (2007) Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians. Arch Intern Med 167 1533-1538
336. GJ Canaris, NR Manowitz, G Mayor and EC Ridgway (2000) The Colorado thyroid disease prevalence study. Arch Intern Med 160 526-534
337. KA Woeber (2005) Observations concerning the natural history of subclinical hyperthyroidism. Thyroid 15 687-691
338. NF Col, MI Surks and GH Daniels (2004) Subclinical thyroid disease: clinical applications. JAMA 291 239-243
339. E Roti and ED Uberti (2001) Iodine excess and hyperthyroidism. Thyroid 11 493-500
340. BL Baltisberger, CE Minder and H Burgi (1995) Decrease of incidence of toxic nodular goitre in a region of Switzerland after full correction of mild iodine deficiency. Eur J Endocrinol 132 546-549
341. PN Taylor, OE Okosieme, CM Dayan and JH Lazarus (2014) Therapy of endocrine disease: impact of iodine supplementation in mild-to-moderate iodine deficiency: systematic review and meta-analysis. Eur J Endocrinol 170 R1-R15
342. JE Fradkin and J Wolff (1983) Iodide-induced thyrotoxicosis. Medicine 62 1-20
343. FIR Martin, BW Tress, PG Colman and DR Deam (1993) Iodine-induced hyperthyroidism due to nonionic contrast radiography in the elderly. Am J Med 95 78-82
344. JJ Conn, MJ Sebastian, D Deam, et al. (1996) A prospective study of the effect of nonionic contrast media on thyroid function. Thyroid 6 107-110
345. JE Lawrence, SH Lamm and LE Braverman (1999) The use of perchlorate for the prevention of thyrotoxicosis in patients given iodine rich contrast agents. J Endocrinol Invest 22 405-407
346. E Martino, L Bartalena, F Bogazzi and LE Braverman (2001) The effects of amiodarone on the thyroid. Endocr Rev 22 240-254
347. TC Smyrk, JR Goellner, MD Brennan and JA Carney (1987) Pathology of the thyroid in amiodarone-associated thyrotoxicosis. Am J Surg Pathol 11 197-204
348. J Cohen-Lehman, P Dahl, S Danzi and I Klein (2010) Effects of amiodarone therapy on thyroid function. Nat Rev Endocrinol 6 34-41
349. SE Eaton, HA Euinton, CM Newman, et al. (2002) Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. Clin Endocrinol (Oxf) 56 33-38
350. F Osman, JA Franklyn, MC Sheppard and MD Gammage (2002) Successful treatment of amiodarone-induced thyrotoxicosis. Circulation 105 1275-1277
351. EN Pearce, AP Farwell and LE Braverman (2003) Thyroiditis. N Engl J Med 348 2646-2655
352. F Bogazzi, L Tomisti, L Bartalena, et al. (2012) Amiodarone and the thyroid: a 2012 update. J Endocrinol Invest 35 340-348
353. GH Daniels (2001) Amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 86 3-8
354. LE Ryan, LE Braverman, DS Cooper, et al. (2004) Can amiodarone be restarted after amiodarone-induced thyrotoxicosis? Thyroid 14 149-153
355. P Beck-Peccoz, A Lania, A Beckers, et al. (2013) 2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J 2 76-82
356. S Refetoff, RE Weiss and SJ Usala (1993) The syndromes of resistance to thyroid hormone. Endocr Rev 14 348-399
357. S Refetoff, RE Weiss, SJ Usala and Y Hayashi (1994) The syndromes of resistance to thyroid hormone: update 1994. Endocr Rev 3 336-342
358. P Beck-Peccoz, D Mannavola and L Persani (2005) Syndromes of thyroid hormone resistance. Ann Endocrinol (Paris) 66 264-269
359. AE Pekary, IM Jackson, TM Goodwin, et al. (1993) Increased in vitro thyrotropic activity of partially sialated human chorionic gonadotropin extracted from hydatidiform moles of patients with hyperthyroidism. J Clin Endocrinol Metab 76 70-74
360. J Desai, L Yassa, E Marqusee, et al. (2006) Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145 660-664
361. F Illouz, D Braun, C Briet, et al. (2014) Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors. Eur J Endocrinol 171 R91-R99
362. F Sarvghadi, M Hedayati, Y Mehrabi and F Azizi (2005) Follow up of patients with postpartum thyroiditis: a population-based study. Endocrine 27 279-282
363. A Stagnaro-Green, A Schwartz, R Gismondi, et al. (2011) High rate of persistent hypothyroidism in a large-scale prospective study of postpartum thyroiditis in southern Italy. J Clin Endocrinol Metab 96 652-657
364. AP Weetman, RC Smallridge, TB Nutman and KD Burman (1987) Persistent thyroid autoimmunity after subacute thyroiditis. J Clin Lab Immunol 23 1-6
365. LK Koh, FS Greenspan and PP Yeo (1997) Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 7 891-896
366. Y Tomer (2010) Hepatitis C and interferon induced thyroiditis. J Autoimmun 34(3), J322-J326
367. F Doi, S Kakizaki, H Takagi, et al. (2005) Long-term outcome of interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. Liver Int 25 242-246
368. KK Miller and GH Daniels (2001) Association between lithium use and thyrotoxicosis caused by silent thyroiditis. Clin Endocrinol (Oxf) 55 501-508
369. C Baethge, H Blumentritt, A Berghofer, et al. (2005) Long-term lithium treatment and thyroid antibodies: a controlled study. J Psychiatry Neurosci 30 423-427
370. OP Hamnvik, PR Larsen and E Marqusee (2011) Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst 103 1572-1587
371. JW de Groot, BA Zonnenberg, JT Plukker, et al. (2005) Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 78 433-438
372. CW Hedberg, DB Fishbein, RS Janssen, et al. (1987) An outbreak of thyrotoxicosis caused by the consumption of bovine thyroid gland in ground beef. N Engl J Med 316(16), 993-998
373. CP DeSimone, SM Lele and SC Modesitt (2003) Malignant struma ovarii: a case report and analysis of cases reported in the literature with focus on survival and I131 therapy. Gynecol Oncol 89 543-548
374. T Dunzendorfer, A deLas Morenas, T Kalir and RM Levin (1999) Struma ovarii and hyperthyroidism. Thyroid 9 499-502
375. SA Giralt, F Dexeus, R Amato, et al. (1992) Hyperthyroidism in men with germ cell tumors and high levels of beta-human chorionic gonadotropin. Cancer 69 1286-1290
376. MI Dujardin, P Sekhri and LW Turnbull (2014) Struma ovarii: role of imaging? Insights Imaging 5(1), 41-51
377. MR Bayot and IJ Chopra (1995) Coexistence of struma ovarii and Graves' disease. Thyroid 5 469-471
378. MH Snow, T Davies, BR Smith, et al. (1979) Thyroid stimulating anti­bodies and metastatic thyroid carcinoma. Clin Endocrinol (Oxf) 10 413-418
379. C Als, P Gedeon, H Rosler, et al. (2002) Survival analysis of 19 patients with toxic thyroid carcinoma. J Clin Endocrinol Metab 87 4122-4127